Updates on the Prevention and Management of CINV

Topics Covered

Types of CINV

Emetogenic Potential of Regimens

Patient-Related Risk Factors

Why It Is Important to Prevent CINV

What Does Prophylaxis Involve?

Therapies for Preventing or Treating CINV

Clinical Practice Guidelines for Preventing and Managing CINV

MASCC Recommendations for Preventing Acute Nausea and Vomiting

MASCC Recommendations for Delayed Nausea and Vomiting

Challenges: Nonadherence to Practice Guidelines

Clark-Snow et al Findings

More Recently Approved Therapies

Rolapitant: Schwartzberg et al

Rolapitant: Schwartzberg et al (cont)

Rolapitant: Rapoport et al

Rolapitant: Navari et al

Rolapitant: Aapro et al

NEPA: Approval

NEPA: Gralla et al Phase 3 Trial

NEPA: Aapro et al Phase 3 Trial

NEPA: Feyer et al

NEPA: Aapro et al Post Hoc Safety Analysis

Palonosetron in Triplet Regimen

Palonosetron in Triplet Regimen (cont)

Aprepitant: Kang et al

Kang et al: CR Rate

Olanzapine: Navari et al

Navari et al Study Findings

Navari et al Study Findings (cont)

Olanzapine: Chiu et al

APF530: A New 5-HT3 RA Formulation

Updated Clinical Practice Guidelines

Updated ASCO Guidelines

Summary of Key Points

Abbreviations

Abbreviations (cont)